FDA's Progress Under Commissioner Marty Makary

Food and Drug Administration (FDA) Commissioner Marty Makary marked his first year in office by highlighting significant improvements within the agency, which he attributes to a recovery from cuts implemented by the Trump administration's Department of Government Efficiency (DOGE). During a recent press call, Makary noted an increase in new medication approvals and reduced review times, emphasizing the FDA's integration of artificial intelligence tools to enhance the evaluation process. He clarified that while AI assists in demonstrating the concordance of applications with existing approved products, it does not replace human decision-making.

The Hill

Makary addressed the impact of staffing reductions that occurred under DOGE, where approximately 3,500 employees received Reduction In Force notices. Many of these staff members were later reinstated, contributing to what Makary described as "significant progress in healing" the agency. He expressed his commitment to retaining experienced staff and avoiding major reorganizations, which he believes has fostered a more stable environment for the FDA's operations.

The Hill

In his remarks, Makary stated, “I came to the FDA at a very tough time... It was a hard time for the agency, and I plan to acknowledge that with the staff today when I talk to them.” He emphasized the importance of staff retention and the positive changes that have followed the reinstatement of personnel.

The Hill

While Makary's tenure has been characterized by improvements, some critics argue that the reliance on AI tools may lead to overconfidence in technology at the expense of thorough human review. Concerns have been raised about the potential for AI to influence decision-making processes, despite assurances that it is merely a supportive tool.

The Hill

Looking ahead, the FDA is expected to continue its focus on enhancing drug approval processes and integrating advanced technologies. The agency's recent approval of Eli Lilly's weight-loss pill, Foundayo, exemplifies its commitment to expediting access to new medications.

The Hill

• “The AIs are not making decisions on the drugs, but the AI tool can demonstrate the concordance rate of an application with other approved products.” — Marty Makary, FDA Commissioner

The Hill

• “I came to the FDA at a very tough time, immediately following the DOGE restructuring.” — Marty Makary, FDA Commissioner

The Hill

In summary, Commissioner Marty Makary's first year has been marked by efforts to restore the FDA's operational capacity following significant staffing cuts, with a focus on innovation and efficiency in drug approval processes.

The Hill